188 related articles for article (PubMed ID: 32232485)
1. AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.
Mujahed H; Miliara S; Neddermeyer A; Bengtzén S; Nilsson C; Deneberg S; Cordeddu L; Ekwall K; Lennartsson A; Lehmann S
Blood; 2020 Jul; 136(3):339-352. PubMed ID: 32232485
[TBL] [Abstract][Full Text] [Related]
2. CTCF boundary remodels chromatin domain and drives aberrant
Luo H; Wang F; Zha J; Li H; Yan B; Du Q; Yang F; Sobh A; Vulpe C; Drusbosky L; Cogle C; Chepelev I; Xu B; Nimer SD; Licht J; Qiu Y; Chen B; Xu M; Huang S
Blood; 2018 Aug; 132(8):837-848. PubMed ID: 29760161
[No Abstract] [Full Text] [Related]
3. Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.
Ghasemi R; Struthers H; Wilson ER; Spencer DH
Leukemia; 2021 Feb; 35(2):404-416. PubMed ID: 32398790
[TBL] [Abstract][Full Text] [Related]
4. HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia.
Luo H; Zhu G; Eshelman MA; Fung TK; Lai Q; Wang F; Zeisig BB; Lesperance J; Ma X; Chen S; Cesari N; Cogle C; Chen B; Xu B; Yang FC; So CWE; Qiu Y; Xu M; Huang S
Mol Cell; 2022 Feb; 82(4):833-851.e11. PubMed ID: 35180428
[TBL] [Abstract][Full Text] [Related]
5. NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia.
Wang AJ; Han Y; Jia N; Chen P; Minden MD
Leukemia; 2020 May; 34(5):1278-1290. PubMed ID: 31831844
[TBL] [Abstract][Full Text] [Related]
6. Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid Leukemia.
Zha J; Lai Q; Deng M; Shi P; Zhao H; Chen Q; Wu H; Xu B
Stem Cell Rev Rep; 2020 Dec; 16(6):1280-1291. PubMed ID: 33057942
[TBL] [Abstract][Full Text] [Related]
7. Gain of DNA methylation is enhanced in the absence of CTCF at the human retinoblastoma gene promoter.
Dávalos-Salas M; Furlan-Magaril M; González-Buendía E; Valdes-Quezada C; Ayala-Ortega E; Recillas-Targa F
BMC Cancer; 2011 Jun; 11():232. PubMed ID: 21663659
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5.
Dluhosova M; Curik N; Vargova J; Jonasova A; Zikmund T; Stopka T
PLoS One; 2014; 9(2):e87448. PubMed ID: 24498324
[TBL] [Abstract][Full Text] [Related]
9. Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
Leung KK; Nguyen A; Shi T; Tang L; Ni X; Escoubet L; MacBeth KJ; DiMartino J; Wells JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):695-700. PubMed ID: 30584089
[TBL] [Abstract][Full Text] [Related]
10. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
[TBL] [Abstract][Full Text] [Related]
11. Integrative characterization of G-Quadruplexes in the three-dimensional chromatin structure.
Hou Y; Li F; Zhang R; Li S; Liu H; Qin ZS; Sun X
Epigenetics; 2019 Sep; 14(9):894-911. PubMed ID: 31177910
[TBL] [Abstract][Full Text] [Related]
12. RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.
Romanova EI; Zubritskiy AV; Lioznova AV; Ogunleye AJ; Golotin VA; Guts AA; Lennartsson A; Demidov ON; Medvedeva YA
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232714
[TBL] [Abstract][Full Text] [Related]
13. Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
Qu Y; Siggens L; Cordeddu L; Gaidzik VI; Karlsson K; Bullinger L; Döhner K; Ekwall K; Lehmann S; Lennartsson A
Blood; 2017 Feb; 129(7):e13-e25. PubMed ID: 28003272
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
[TBL] [Abstract][Full Text] [Related]
15. The increasing genomic complexity of acute myeloid leukemia.
Rowe JM
Best Pract Res Clin Haematol; 2014; 27(3-4):209-13. PubMed ID: 25455268
[TBL] [Abstract][Full Text] [Related]
16. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.
Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Siedlecki JA
Mol Med Rep; 2015 May; 11(5):3948-54. PubMed ID: 25585874
[TBL] [Abstract][Full Text] [Related]
17. The murine IgH locus contains a distinct DNA sequence motif for the chromatin regulatory factor CTCF.
Ciccone DN; Namiki Y; Chen C; Morshead KB; Wood AL; Johnston CM; Morris JW; Wang Y; Sadreyev R; Corcoran AE; Matthews AGW; Oettinger MA
J Biol Chem; 2019 Sep; 294(37):13580-13592. PubMed ID: 31285261
[TBL] [Abstract][Full Text] [Related]
18. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.
Agrawal S; Hofmann WK; Tidow N; Ehrich M; van den Boom D; Koschmieder S; Berdel WE; Serve H; Müller-Tidow C
Blood; 2007 May; 109(9):3895-905. PubMed ID: 17234736
[TBL] [Abstract][Full Text] [Related]
19. Distinct gene expression pattern of RUNX1 mutations coordinated by target repression and promoter hypermethylation in acute myeloid leukemia.
Li J; Jin W; Tan Y; Wang B; Wang X; Zhao M; Wang K
Front Med; 2022 Aug; 16(4):627-636. PubMed ID: 34958450
[TBL] [Abstract][Full Text] [Related]
20. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
